potential indications for glp-1 receptor agonists keep expanding GLP-1/GIP RA Summary Sheet and Beyond! Can one drug do it
Description
Lancet 2023;402:61326.PubMed 94
[DOI] [PMC free article] [PubMed] [Google Scholar] 103.Knerr P.J., Mowery S.A., Finan B., Perez-Tilve D., Tschp M.H., DiMarchi R.D
Well, you're not the only one
Falko JM, Crockett SE, Cataland S, Mazzaferri EL
A record 7.8% in spending growth in 2023 across Rhode Islands health system was partially driven by a surging amount of GLP-1 prescriptions, which doubled from 2022 to 2023
However, metformin is oral, inexpensive, and has an extensive safety record, making it the preferred initial therapy
